Imugene logo

IMU - Imugene Share Price

A$0.037 0.0  2.8%

Last Trade - 5:10am

Sector
Healthcare
Size
Small Cap
Market Cap £67.9m
Enterprise Value £58.6m
Revenue £2.37m
Position in Universe 608th / 1828
Bullish
Bearish
Unlock IMU Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

IMU Revenue Unlock IMU Revenue

Net Income

IMU Net Income Unlock IMU Revenue

Normalised EPS

IMU Normalised EPS Unlock IMU Revenue

PE Ratio Range

IMU PE Ratio Range Unlock IMU Revenue

Dividend Yield Range

IMU Dividend Yield Range Unlock IMU Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IMU EPS Forecasts Unlock IMU Revenue
Profile Summary

Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated May 30, 1986
Public Since December 2, 1993
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 3,609,847,749
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address L 3 62 Lygon Street, MELBOURNE, 3053, Australia
Web http://www.imugene.com/
Phone +61 3 98245254
Contact ()
Auditors Grant Thornton Audit Pty Ltd
IMU Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for IMU
Upcoming Events for IMU
Similar to IMU
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.